ChenS., XieP., CowanM., et al.Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. The Journal of Clinical Investigation, 132(14):e158800 (2022).
5.
ChiappinelliK.B., StrisselP.L., DesrichardA., et al.Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell, 162(5):974–986 (2015).
6.
RouloisD., Yau.H.L., SinghaniaR., et al.DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell, 162(5):961–973 (2015).
7.
TopperM.J., VazM., ChiappinelliK.B., et al.Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell, 171(6):1284–1300.e21 (2017).
8.
OrsolicI., CarrierA., EstellerM. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends in Genetics, 39(1):74–88 (2023).
9.
SongH., LiuD., DongS., et al.Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy, 5, article number: 193 (2020).
10.
PidsleyR., LamD., QuW., et al.Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality. Clinical and Translational Medicine, 12(10) :e1030 (2022).
11.
U.S. National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Female Breast Cancer. seer.cancer.gov/statfacts/html/breast.html
12.
CaiW.L., ChenJ.F-Y., ChenH., et al.Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. eLife, 11:e78163 (2022).
13.
Casado-PelaezM., Bueno-CostaA., EstellerM. Single cell cancer epigenetics. Trends in Cancer, 8(10);820–838 (2022).
